Federal Register #E10420250

Monoclonal Antibody 18H2 for Eos Detection Licensing Opportunity

NIAID, part of NIH under HHS, is offering a government-owned monoclonal antibody for licensing: - Government buyer: - National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), Department of Health and Human Services (HHS) - OEM and developer: - NIAID (National Institute of Allergy and Infectious Diseases) - Product requested/offered: - Monoclonal antibody 18H2 for specific detection of the transcription factor Eos (Ikzf4) in regulatory T cells - Part number: E10420250 - Detects Eos in both human and mouse Treg cells - Suitable for research and diagnostic applications (autoimmune diseases, cancer, organ transplants) - Unique requirements and notable details: - Technology is available for licensing and collaborative research - Intellectual property referenced as HHS Reference No. E10420250 - Competitive advantages in immune monitoring and biomarker discovery - Place of performance and delivery: - NIAID, 5601 Fishers Lane, Rockville, MD 20852 - NIH Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), announces the availability of a government-owned invention for licensing. The invention is a monoclonal antibody (18H2) for specific detection of the transcription factor Eos (Ikzf4) in regulatory T cells, which is important for immune system balance and preventing autoimmunity. This antibody accurately detects Eos in both human and mouse Treg cells and is useful for research and potential commercial applications such as diagnostic tests for autoimmune diseases, cancer treatments, and organ transplants. Licensing and collaborative research opportunities are available to further develop and commercialize this technology.

View original listing